Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04300231
Other study ID # 1905006917
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date October 22, 2019
Est. completion date June 30, 2023

Study information

Verified date May 2023
Source Indiana University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to compare the difference between four different pain control methods in patients who will be having a cystectomy surgery (surgical removal of the bladder).


Description:

The purpose of this study is to compare the difference between four different pain control methods in patients who will be having a cystectomy surgery (surgical removal of the bladder). By collecting this data, we aim to show improved postoperative pain scores, decreased opioid needs, and decreased opioid side effects (feeling sick to your stomach, feeling drowsy/sleepy, blockage/lack of movement in the intestines, inability to completely empty the bladder, unusually slow or shallow breathing). The specific aim of this study is to compare the difference between the pain control methods in achieving the following: 1. Decreased opioid requirements 2. Improved postoperative VAS pain scores 3. Decreased opioid side effects (Nausea, sedation, ileus, respiratory depression) 4. Decreased hospital length of stay (LOS)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 160
Est. completion date June 30, 2023
Est. primary completion date June 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients undergoing cystectomy for bladder cancer - ASA class 1, 2, 3 or 4 - Age 18 or older, male or female - Desires Regional anesthesia for postoperative pain control Exclusion Criteria: - Any contraindication for thoracic epidural. - History of substance abuse in the past 6 months. - Patients on more than 30mg morphine equivalents of opioids daily. - Any physical, mental or medical conditions which in the opinion of the investigators, may confound quantifying postoperative pain resulting from surgery. - Known allergy or other contraindications to the study medications (Acetaminophen, Gabapentin, Bupivacaine, Hydromorphone). - Postoperative intubation. - Any patient with history of neuropathic bowel or bladder dysfunction

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
epidural bupivacaine 0.05%
Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
Liposomal bupivacaine
20 ml
bupivacaine 0.125%
40 mL
bupivacaine 0.5%
60 mL
/hydromorphone 0.05mg/ml
Mix of epidural bupivacaine 0.05% and hydromorphone 0.05mg/ml will be given using PCEA.
injectable saline
40 mL

Locations

Country Name City State
United States Indiana Univeristy Indianapolis Indiana

Sponsors (1)

Lead Sponsor Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

References & Publications (10)

Butterworth Iv, John F., David C. Mackey, and John D. Wasnick.

de Boer, H. D., O. Detriche, and P. Forget.

Guo, Q., R. Li, L. Wang, D. Zhang, and Y. Ma.

Hou, X., Z. Luo, H. Wang, Y. Zhan, L. Yang, and L. Li.

Kalogera, E., J. N. Bakkum-Gamez, A. L. Weaver, J. P. Moriarty, B. J. Borah, C. L. Langstraat, C. J. Jankowski, et al.

Ladjevic N, Likic-Ladjevic I, Dzamic Z, Acimovic M, Dragicevic D, Durutovic O. Combined general and epidural anaesthesia versus general anaesthesia for radical cystectomy. Acta Chir Iugosl. 2007;54(4):89-91. doi: 10.2298/aci0704089l. — View Citation

Mazul-Sunko B, Gilja I, Jelisavac M, Kozul I, Troha D, Osmancevic N, El-Saleh A, Markic A, Kovacevic M, Bokarica P. Thoracic epidural analgesia for radical cystectomy improves bowel function even in traditional perioperative care: a retrospective study in eighty-five patients. Acta Clin Croat. 2014 Sep;53(3):319-25. — View Citation

ozek, J. J., M. De Ruyter, and T. W. Khan.

Ozyuvaci E, Altan A, Karadeniz T, Topsakal M, Besisik A, Yucel M. General anesthesia versus epidural and general anesthesia in radical cystectomy. Urol Int. 2005;74(1):62-7. doi: 10.1159/000082712. — View Citation

Sun, J. X., K. Y. Bai, Y. F. Liu, G. Du, Z. H. Fu, H. Zhang, J. H. Yang, et al.

Outcome

Type Measure Description Time frame Safety issue
Primary VAS score at 48 hour The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain Pain scores will be measured 48 hours after surgery
Primary VAS score at 72 hour The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain Pain scores will be measured 72 hours after surgery
Secondary Secondary endpoint includes total opioid consumption at 1 hour Opioid consumption will be collected by a study team member post operatively at hour 1 per protocol time requirements Opioid comsumption will be measured at 1 hour
Secondary Secondary endpoint includes total opioid consumption at 24 hours Opioid consumption will be collected by a study team member post operatively at hour 24 per protocol time requirements Opioid comsumption will be measured at 24 hours
Secondary Secondary endpoint includes total opioid consumption at 48 hours Opioid consumption will be collected by a study team member post operatively at hour 48 per protocol time requirements Opioid comsumption will be measured at 48 hours
Secondary Secondary endpoint includes total opioid consumption at 72 hours Opioid consumption will be collected by a study team member post operatively at hour 72 per protocol time requirements Opioid comsumption will be measured at 72 hours
Secondary Secondary endpoint includes total opioid consumption at 96 hours Opioid consumption will be collected by a study team member post operatively at hour 96 per protocol time requirements Opioid comsumption will be measured at 96 hours
Secondary VAS score at 1 hour The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain Pain scores will be measured 1 hour after surgery
Secondary VAS score at 24 The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain Pain scores will be measured 24 hours after surgery
Secondary VAS score at 96 hour The VAS score will be taken with both rest and movement (knee flexion) and will be measured by a study team investigator using Visual Analog Scale (VAS). Using a scale of 0-10 for documentation with 10 being the worst pain and 0 being no pain Pain scores will be measured 96 hours after surgery
Secondary Average Nausea score 1 hour Nausea scores will be collected by study team member post operatively at hour 1 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3). 1 hour
Secondary Average Nausea score 24 hour Nausea scores will be collected by study team member post operatively at hour 24 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3). 24 hour
Secondary Average Nausea score 48 hour Nausea scores will be collected by study team member post operatively at hour 48 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3). 48 hour
Secondary Average Nausea score 72 hour Nausea scores will be collected by study team member post operatively at hour 72 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3). 72 hour
Secondary Average Nausea score 96 hour Nausea scores will be collected by study team member post operatively at hour 96 per protocol. Nausea will be recorded as none, mild, moderate or severe. Scoring system being (none=0, mild=1, moderate=2 and severe=3). 96 hour
Secondary Average Sedation score at 1 hour Sedation scores will be collected by a study team member post operatively at hour 1 per protocol requirements. Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome. 1 hour
Secondary Average Sedation score at 24 hour Sedation scores will be collected by a study team member post operatively at hour 24 per protocol requirements. Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome. 24 hour
Secondary Average Sedation score at 48 hour Sedation scores will be collected by a study team member post operatively at hour 48 per protocol requirements. Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher scores mean a worse outcome. 48 hour
Secondary Average Sedation score at 72 hour Sedation scores will be collected by a study team member post operatively at hour 72 per protocol requirements. Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome. 72 hour
Secondary Average Sedation score at 96 hour Sedation scores will be collected by a study team member post operatively at hour 96 per protocol requirements. Determining if patient is awake & alert=0, quietly awake=1, asleep and arousable=2 or deep sleep=3. The higher the scores mean a worse outcome. 96 hour
Secondary First Flatus-bowel movement The passing of gas will be collected by a study team member as per protocol requirements. This is only for the first time the patients passes gas post operatively and is expected to occur during the hospital admission prior to patients discharge. The outcome measure will be assessed through study completion, an average of 1week. Assess daily until patient passes gas postoperatively within 72 hours
Secondary Incidence of Urinary Retention-Postoperative Creatinine Lab level of Creatinine will be collected if only ordered by the surgeon doing the surgery. I will be recorded or documented for 4 days post operatively. Creatinine level will be collected daily postoperatively for 4 days
Secondary Time to Discharge-Length of Stay LOS will be collected via EMR From hospital admission to discharge date up to 3weeks
Secondary Incidence of Hypotension Defined as BP decrease of more than 20% from baseline daily during 96 hour assessment period
Secondary Incidence of Respiratory Depression Define by use of Narcan assess daily as yes/no
Secondary Ambulation Activity Define as anytime out of bed: up in chair, to bathroom or walking hall with PT/nurse will be recorded daily as yes/no
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05037552 - Benefit of Hemostatic Sealant in Preservation of Ovarian Reserve N/A
Terminated NCT03500744 - Erector Spinae Plane Block for Major Gynecologic and Urologic Surgery N/A
Recruiting NCT04118712 - Pediatric Ovarian Tissue Banking - Operative Specimens From Females 0-18 Years of Age
Completed NCT02238886 - Radical Cystectomy, Nutrition and Convalescence N/A
Not yet recruiting NCT06002269 - A Home-based Lifestyle Intervention for Optimizing Surgical Outcomes Among Urinary Bladder Cancer Patients N/A
Completed NCT04028934 - Study of the Quality of Life of Patients Treated by Heavy Surgery as Part of an Enhanced Recovery at Beau Soleil Clinic- QUALICHIR
Recruiting NCT05715684 - Patient-Centered Surgical Prehabilitation N/A
Recruiting NCT00454038 - Study of Collagen Membrane in Guided Bone Regeneration Phase 1/Phase 2
Completed NCT02665156 - Time Efficiency of Intracorporeal Orthotopic Diversion With Robotic Staplers After Robot Assisted Radical Cystectomy N/A
Terminated NCT01245660 - A Phase 0 of Neoadjuvant Lapatinib in Infiltrative Bladder Carcinoma Before Cystectomy Phase 0
Recruiting NCT03280459 - Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction N/A
Completed NCT00969514 - Robotic-Assisted Laparoscopic Cystectomy N/A
Completed NCT00577785 - Study to Obtain Full Thickness Bladder Tissue From Subjects Undergoing Cystectomy Surgery N/A